![]() Results are expected by the middle of next year.ĬYBN also has deuterated tryptamines CYB003 and CYB004 in its preclinical pipeline, which it is developing for alcohol-use disorder and anxiety, respectively. The first is an open-label BE study, and the second is a double-blind placebo controlled study of dose escalation and safety, with 80 patients on the drug and 40 on the placebo. The drug candidate is currently undergoing Phase IIA and Phase IIB clinical trials. The drug is a psilocybin derivative administered through a sublingual film – that is, a dissolving film that is placed under the tongue there are no pills to swallow or injections to take. The leading candidate in the pipeline, CYB001, is a proposed treatment for major depressive disorder. The company is using a combination of a novel drug discovery platform, proprietary drug delivery systems, and an innovative treatment regimen to improve the efficacy of mental health treatments. In its development program, Cybin is following a ‘3 pillar’ strategy. Cybin has completed over 50 pre-clinical studies, and now has a few active pipeline projects, targeting major depressive disorder, anxiety disorders and alcohol addiction. Cybin has 14 patent filings to its credit, covering novel psychedelic compounds, drug delivery mechanisms, and a drug discovery pipeline of novel tryptamines and phenethylamines. The company works with psychedelic therapeutics to develop new treatment for depression, anxiety, and addictive disorders. We will start with Cybin, a biopharmaceutical company with a focus on mental health. We’re talking about over 200% upside potential here. Both tickers boast a Strong Buy consensus rating and bring massive growth prospects to the table. These experts bring in-depth knowledge of the industries they cover and substantial experience to the table.īearing this in mind, we used TipRanks’ database to find two compelling penny stocks, according to Wall Street analysts. ![]() So, how should investors approach a potential penny stock investment? By taking a cue from the analyst community. The risk involved with these plays scares off the faint-hearted as very real problems like weak fundamentals or overwhelming headwinds could be masked by the low share prices. That said, there’s a legitimate reason some investors are wary when it comes to cheap stocks. What’s more, even what feels like trivial share price appreciation can translate to massive percentage gains. The bargain price points allow investors to snap up more shares than possible when investing in other more well-known names. ![]() When we say high return potential, we aren’t exaggerating. These tickers changing hands for less than $5 per share either draw investors in with their high return potential or send them running for the hills, but why? Wall Street has mixed feelings about penny stocks.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |